EPCORE CLL-1: A trial testing epcoritamab in people with relapsed or refractory chronic lymphocytic leukaemia and Richter’s syndrome

This is a phase 1 and 2 trial testing a medication called epcoritamab in patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) or Richter’s syndrome that has come back after (relapsed) or not responded to (refractory) treatment.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04623541

Trial aim and background  

The aim of this trial is to study the medication epcoritamab both alone and in combination with other medications in patients with relapsed or refractory CLL or Richter’s syndrome. Epcoritamab is an antibody. When given in combination it will be given with either:

  • Venetoclax
  • Lenalidomide or,
  • R-CHOP

The first part of the trial will be looking at the best dose of epcoritamab as well as how safe it is. The second part will look at how effective and well tolerated it is.

Part of this trial is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter 

Patients with CLL/SLL which has failed to respond to two previous treatments and still requires treatment may be eligible for this trial. In addition patients with diffuse large B-cell lymphoma on a background of CLL/SLL, and therefore Richter’s syndrome may be eligible.

Locations 

Recruitment is taking place in the following UK locations:

  • Barts Hospital, London
  • Royal Cornwall Hospital, Truro

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT04623541

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.